GeneDx Holdings Corp. Restructuring and Related Cost, Expected Number of Positions Eliminated
GeneDx Holdings Corp. (WGS) reported Restructuring and Related Cost, Expected Number of Positions Eliminated of 250 position for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated · last filed 2023-08-08
- GeneDx Holdings Corp. restructuring and related cost, expected number of positions eliminated for the quarter ending 2022-09-30 was 250.00 position.
- GeneDx Holdings Corp. restructuring and related cost, expected number of positions eliminated for fiscal 2022 was 250.00 position.
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated | Restructuring and Related Cost, Expected Number of Positions Eliminated 3 month | Restructuring and Related Cost, Expected Number of Positions Eliminated 12 month |
|---|---|---|---|
| 2022-12-31 | 250.00 position 10-K · filed 2023-03-16 | ||
| 2022-12-14 | 500.00 position 10-Q · filed 2023-08-08 | ||
| 2022-11-14 | 500.00 position 10-Q · filed 2023-05-09 | ||
| 2022-09-30 | 250.00 position 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |